Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.39 USD
Change Today -0.37 / -4.77%
Volume 2.0M
ACHN On Other Exchanges
As of 8:10 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Mary Kay Fenton

Chief Financial Officer, Executive Vice President and Secretary,Achillion Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 1 different industries.

As of Fiscal Year 2014


Ms. Mary Kay Fenton serves as the Chief Financial Officer and Secretary of Achillion Pharmaceuticals, Inc. Ms. Fenton has been an Executive Vice President of Achillion Pharmaceuticals, Inc. since March 6, 2014. She served as a Senior Vice President of Achillion Pharmaceuticals from 2010 to March 6, 2014 and also served as its Vice President until 2010. She served as Vice President of Finance & Administration at Achillion Pharmaceuticals Inc. She has led Achillion Pharmaceuticals ...

Read Full Background

Corporate Headquarters*

300 George Street
New Haven, Connecticut 06511

United States

Phone: 203-624-7000
Fax: 203-624-7003

Board Members Memberships*

There is no Board Members Memberships data available.


College of the Holy Cross
University of Connecticut, School of Business Administration

Other Affiliations*

Annual Compensation*

Total Annual Compensation$347,679

Stock Options*

All Other Compensation$8,124
Exercisable Options563,125
Exercisable Options Value$4,049,009
Unexercisable Options418,750
Unexercisable Options Value$2,337,425
Total Value of Options$6,386,433
Total Number of Options981,875

Total Compensation*

Total Annual Cash Compensation$514,282
Total Short Term Compensation$347,679
Other Long Term Compensation$8,124
Total Calculated Compensation$1,723,718
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACHN:US $7.39 USD -0.37


Pascal Soriot Chief Executive Officer, Executive Director and Member of Disclosure Committee
AstraZeneca PLC
3.1M GBP
M. Michelle Berrey M.D., MPH.Chief Executive Officer, President, Chief Medical Officer and Director
Chimerix, Inc.
John M. Gill CPAChief Executive Officer, President and Director
PharmAthene, Inc.
Paul Chaplin MSc, Ph.D.Chief Executive Officer and President
Bavarian Nordic A/S
Daniel J. Abdun-Nabi Chief Executive Officer, President, Director, Member of Strategic Operations Committee and Member of Pricing Committee
Emergent BioSolutions, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACHILLION PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at